Trial Search Results

VTX-2337 in Combination With Radiotherapy in Patients Low-Grade B-cell Lymphomas

This study is to determine the safety and effectiveness of VTX-2337 (an investigational drug that stimulates the immune system) in combination with radiation therapy in treating patients with low-grade B-cell lymphoma. Patients will receive 2 low doses of radiotherapy, and 9 intratumoral injections of VTX-2337 over the course of 3 months.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Celgene

Collaborator: Stanford University

Stanford Investigator(s):

Intervention(s):

  • Drug: VTX-2337 plus radiotherapy

Phase:

Phase 1/Phase 2

Eligibility


Major Inclusion Criteria:

   - low grade B cell lymphoma

   - 1 or more sites of disease appropriate for intratumoral injection

   - measurable disease other than the injection site

   - Performance Status of 1 or better

   - Adequate bone marrow, renal and hepatic function

   - No active autoimmune disease or systemic immunosuppressive drugs

   - Life expectancy > 4 months

Exclusion Criteria:

   - Known HIV

   - Known brain metastases

   - Malignancy within last 5 yrs (basal cell or non-invasive squamous cell carcinoma OK)

   - Anticoagulation therapy other than 325mg QD ASA

   - Significant cardiovascular disease

   - Pregnant or nursing

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study

All

Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Lori Richards
6507258589
Not Recruiting